Roche Buys Covid Treatment Rights From Atea in $350 Million Deal

(Bloomberg) -- Roche Holding AG agreed to pay $350 million in an alliance with Atea Pharmaceuticals Inc. to develop a potential treatment for Covid-19.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.